Use of Mirvetuximab Soravtansine for Platinum-Resistant Epithelial Ovarian Cancer Patients

Description: Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of his current clinical studies, which focus on the use of mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer patients

Abstract 5547: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts

Abstract TPS5607: FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer
Shared By : AnnualMeeting2017
Posted on : 06/05/17
Added : 6 months ago
Category : Ovarian Cancer


Nothing found.

More From AnnualMeeting2017

Nothing found.